



**2025 Commercial HMO and PPO Plan Formulary Changes:
Simlandi 20 mg and 80 mg added to the formulary**

Provider Frequently Asked Questions and Answers for Providers

1. Will I need to submit a new prior authorization for Simlandi® for my patient?

- For patients currently using Humira® 20 mg/80 mg and who have an active Blue Shield of California (Blue Shield) authorization on file, a new prior authorization **will not** be required. CVS Specialty Pharmacy® will substitute Simlandi for Humira beginning on January 1, 2026.
- All new prescriptions for Humira 20 mg/80 mg or other non-preferred adalimumab 20 mg/80 mg products will require prior authorization. The patient's response to a trial of Simlandi will be assessed when considering coverage of any non-preferred adalimumab product. To avoid delays, please order Simlandi rather than Humira.
- For members on adalimumab 40 mg, Blue Shield will continue to offer adalimumab-aacf 40 mg on the formulary.

2. Will Blue Shield cover Simlandi 40 mg for my patients?

No, the Simlandi 40 mg strength is a non-preferred product. The preferred adalimumab product for members on the 40 mg dose will continue to be adalimumab-aacf 40 mg.

3. In what strengths and forms is Simlandi available?

Simlandi is available in all the same dosage forms as Humira 20 mg and 80 mg.

- Prefilled syringes: 20 mg/0.2 mL and 80 mg/0.8 mL
- Autoinjector: 80 mg/0.8 mL
- All formulations are citrate-free

4. How should I write prescriptions for Simlandi?

When prescribing, please specify Simlandi on the prescription. There are multiple adalimumab biosimilars available in the marketplace, each with a unique name. The Blue Shield preferred biosimilar for the adalimumab 20 mg and 80 mg strengths is Simlandi (adalimumab-ryvk).

5. Where do I send the new prescriptions for my Blue Shield patient?

For members currently using Humira 20 mg/80 mg, a new prescription is not needed. Since Simlandi is an interchangeable biosimilar, effective January 1, 2026, CVS Specialty Pharmacy will substitute Simlandi for Humira and provide instructions for administration to your patient, along with documentation to you about the change. When renewing prescriptions, however, please order Simlandi to avoid delays.

For members newly starting therapy, send new e-prescriptions for Simlandi to CVS Specialty Pharmacy. Prescriptions may also be faxed to (800) 323-2445 or called in to (800) 237-2767. You may also visit www.CVSspecialty.com for more information.

6. What programs are available from the manufacturer of Simlandi to support this transition?

Teva offers several support programs to assist Blue Shield members. Visit <https://www.simlandihcp.com/savings-and-support/> or call (888) 587-3263 for more information.

Humira® and its design are registered trademarks of AbbVie Biotechnology LTD.

Simlandi® is a registered trademark of Teva Pharmaceuticals, Inc.

CVS Specialty® is a registered trademark of CVS Pharmacy, Inc and/or one of its affiliates